2017年12月10日 · In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell...

2019年10月8日 · Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy in relapsed and refractory diffuse large B-cell lymphoma (DLBCL) patients who have had suboptimal responses to conventional therapies.

2022年9月27日 · Tislecagenleucel (tisa-cel) 和 axicabtagene ciloleucel (axi-cel) 是两种 CAR T 产品，最初均是获批用于治疗≥3线 DLBCL；Tisa-cel 是一种基于 4-1BB 共刺激结构域的二代CAR T，而 axi-cel 是基于CD28。

2023年10月13日 · In this first report of axi-cel (a CD19-directed CAR T-cell therapy using a CD28 costimulatory domain) in combination with a 4–1BB agonist antibody, we demonstrate the feasibility of targeting the 4–1BB pathway to enhance expansion and persistence of axi-cel CAR T …

2022年2月17日 · Methods: In this international, phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with large B-cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy to receive axicabtagene ciloleucel (axi-cel, an autologous anti-CD19 chimeric antigen receptor T-cell therapy) or standard care ...

The CD28 co-stimulatory domain induces faster expansion and differentiation; therefore, axi-cel has advantages in terms of efficacy. However, the 4-1BB co-stimulatory domain can lead to a lower expansion peak and longer persistence, allowing tisa-cel to reduce the incidence of acute toxicity from autologous CAR-T cells.

2022年6月30日 · Three autologous anti-CD19 CAR T-cell products are currently approved by the US Food and Drug Administration (FDA) as third-line treatment and beyond for patients with relapsed or refractory LBCL: axicabtagene ciloleucel (axicel), tisagenlecleucel (tisacel), and lisocabtagene maraleucel (lisocel).

2023年11月2日 · To better understand the efficacy and safety of commercial Axi-cel in Chinese R/R NHL patients in a real-world setting, we conducted this multi-center, non-interventional study (ChiCTR2100047990). The accrual goal is 200 patients, and the primary endpoint is mOS. Here we made the pre-specific interim analysis and the reported the clinical outcomes.

Axicabtagene ciloleucel (axi-cel) is a standard-of-care for patients with relapsed or refractory (r/r) large B cell lymphoma who have received 2 or more lines of prior therapy. Patients receiving axi-cel in the real world could have broader a demographic, disease, and treatment profile compared with that of the cohort in the pivotal ZUMA-1 trial.

2019年3月25日 · Axi-cel is a “second generation” CAR product characterized by the use of a retroviral gene vector transfer and by CD28 as costimulatory domain.